Israel-based Teva Pharmaceutical Industries said on Tuesday it had anticipated and planned for a second generic competitor to its multiple sclerosis treatment Copaxone to enter the market in 2018.

All eyes are on Vertex’s two Phase 3 trials into a triple therapy for cystic fibrosis (CF), in the meantime, however, it’s just received the nod from the FDA for its two therapy combination treatment in the same area.

The JAK inhibitor field is beginning to heat up – AbbVie is soon to enter Phase 3 with its predicted best-in-class therapy, Gilead is working with Galapagos on a potential rival and Celgene started the year off with a...

Biogen has halted its investigation into the efficacy of its humanised monoclonal antibody Tysabri (natalizumab) in the treatment of acute ischemic stroke (AIS) after it failed to meet its primary and secondary...

Advertorial – The 2nd Annual Digi-Tech Pharma 2018 will provide a platform to all its participants an opportunity to interact, share and discuss the digitalization of Pharma industry. Think beyond the pill and...

Persoonsgegevens zijn een gevoelig onderwerp in een wereld waarin we ons meer en meer online begeven. Waar de consument zich dankzij o.a. Arjen Lubach vooral druk maakt om de Wiv (Wet op de inlichtingen en...

De Italiaan Giovanni La Via leidt een delegatie Europarlementariërs die de verhuizing van het Europees Geneesmiddelenbureau (EMA) van Londen naar Amsterdam onder de loep wil nemen.
 

Net als ieder jaar brengen We Are Social en Hootsuite het Global Digital Report samen een rapport uit over de staat van het globale digitale landschap. Met inzichten in het gebruik van internet, social media, mobile en...

De Britse farmaceut GlaxoSmithKline (GSK) heeft de financiële prestaties vorig jaar op alle fronten verbeterd. Het bedrijf zette voor het eerst een omzet van meer dan 30 miljard pond (34 miljard euro) in de boeken...

De uitgaven voor dure geneesmiddelen dreigen de komende jaren te stijgen met vele honderden miljoenen euro’s. Dat blijkt uit een analyse die de NOS heeft gemaakt van de Horizonscan geneesmiddelen die het...

Boehringer Ingelheim has announced its intention to halt development of its candidate BI 409306 in the treatment of Alzheimer’s after it failed to hit its primary endpoints in Phase 2 studies.

President Trump’s rhetoric leading up to his election had the pharmaceutical industry very worried – his often quoted line about drug companies “getting away with murder” was followed by the suggestion that he wanted to...

Novo Nordisk has revealed that its drug Ozempic (semaglutide) has received approval from the European Commission (EC) as a monotherapy for the treatment of type 2 diabetes in patients for whom metformin is inappropriate...

Het Nederlands-Belgische biotechbedrijf is op zoek naar een constructie om overname door farmaceut Gilead te voorkomen. Topman Onno van de Stolpe van Galapagos heeft aangekondigd een beschermmuur te bouwen.

Roche has announced that NICE has issued its final decision to recommend the use of its Gazyvaro (obinutuzumab). The glyco-engineered Type II anti-CD20 monoclonal antibody will now be available on the NHS when used in...

Sanofi has revealed that is has agreed a deal with SK Chemicals, a South Korean vaccine manufacturer, to license its cell culture technology in a $155 million deal.
 

Allergan reported a better-than-expected profit on strong demand, and the company said its migraine treatment met the main goals in a late-stage study.

A combination of experimental drugs from Array BioPharma Inc kept patients with advanced melanoma associated with a common gene mutation alive for nearly three years and twice as long as a rival Roche Holding AG...